A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I

Cancer Research

Volumn 63, Issue 3, 2003, Pages 627-635

  Sachdev, Deepali ^a   Li, Shu Lian ^b   Hartell, Julie S ^a   Fujita Yamaguchi, Yoko ^c   Miller, Jeffrey S ^a   Yee, Douglas ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c TOKAI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWNSTREAM PROCESSING; FEMALE; MITOGENICITY; MONOLAYER CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 3T3 CELLS; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL ADHESION; CELL DIVISION; DOWN-REGULATION; FEMALE; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; INSULIN-LIKE GROWTH FACTOR I; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037308651     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Yu, H., and Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst. (Bethesda), 92: 1472-1489, 2000.
2. Sachdev, D., and Yee, D. The IGF system and breast cancer. Endocr. Relat. Cancer, 8: 197-209, 2001.
3. Dunn, S. E., Hardman, R. A., Kari, F. W., and Barrett, J. C. Insulin-like growth factor I (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res., 57: 2687-2693, 1997.
4. Gooch, J. L., Van Den Berg, C. L., and Yee, D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death: proliferative and anti-apoptotic effects. Breast Cancer Res. Treat., 56: 1-10, 1999.
5. Turner, B. C., Haffty, B. G., Narayanan, L., Yuan, J., Havre, P. A., Gumbs, A. A., Kaplan, L., Burgaud, J. L., Carter, D., Baserga, R., and Glazer, P. M. Insulin-like growth factor 1 receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res., 57: 3079-3083, 1997.
6. Baserga, R., Sell, C., Porcu, P., and Rubini, M. The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Prolif., 27: 63-71, 1994.
7. Resnik, J. L., Reichart, D. B., Huey, K., Webster, N. J., and Seely, B. L. Elevated insulin-like growth factor 1 receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res., 58: 1159-1164, 1998.
8. Baserga, R. Controlling IGF-receptor function: a possible strategy for tumor therapy. Trends Biotechnol., 14: 150-152, 1996.
9. Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., and Ullrich, A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol., 9: 1165-1172, 1989.
10. Fendly, B. M., Winget, M., Hudziak, R. M., Lipari, M. T., Napier, M. A., and Ullrich, A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res., 50: 1550-1558, 1990.
11. Shak, S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin. Oncol., 26: 71-77, 1999.
12. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones. S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
13. Mauro, M. J., and Druker, B. J. STI571: a gene product-targeted therapy for leukemia. Curr. Oncol. Rep., 3: 223-227, 2001.
14. Demetri, G. D. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin. Oncol., 28: 19-26, 2001.
15. Andrews, D. W., Resnicoff, M., Flanders, A. E., Kenyon, L., Curtis, M., Merli, G., Baserga, R., Iliakis, G., and Aiken, R. D. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J. Clin. Oncol., 19: 2189-2200, 2001.
16. Parrizas, M., Gazit, A., Levitzki, A., Wertheimer, E., and LeRoith, D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology, 138: 1427-1433, 1997.
17. Blum, G., Gazit, A., and Levitzki, A. Substrate competitive inhibitors of IGF-I receptor kinase. Biochemistry, 39: 15705-15712, 2000.
18. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (Wash. DC), 237: 178-182, 1987.
19. Hudziak, R. M., Schlessinger, J., and Ullrich, A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA, 84: 7159-7163, 1987.
20. Kull, F. C., Jr., Jacobs, S., Su, Y. F., Svoboda, M. E., Van Wyk, J. J., and Cuatrecasas, P. Monoclonal antibodies to receptors for insulin and somatomedin-C. J. Biol. Chem., 258: 6561-6566, 1983.
21. Arteaga, C. L., and Osborne, C. K. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res., 49: 6237-6241, 1989.
22. Rohlik, Q. T., Adams, D., Kull, F. C., Jr., and Jacobs, S. An antibody to the receptor for insulin-like growth factor 1 inhibits the growth of MCF-7 cells in tissue culture. Biochem. Biophys. Res. Commun., 149: 276-281, 1987.
23. Brunner, N., Yee, D., Kern, F. G., Spang-Thomsen, M., Lippman, M. E., and Cullen, K. J. Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). Eur. J. Cancer, 4: 562-569, 1993.
24. Arteaga, C. L., Kitten, L. J., Coronado, E. B., Jacobs, S., Kull, F. C., Jr., Allred, D. C., and Osbome, C. K. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J. Clin. Investig., 84: 1418-1423, 1989.
25. Li, S. L., Liang, S. J., Guo, N., Wu, A. M., and Fujita-Yamaguchi, Y. Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunol. Immunother., 49: 243-252, 2000.
26. Li, S. L., Kato, J., Paz, I. B., Kasuya, J., and Fujita-Yamaguchi, Y. Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor I receptor. Biochem. Biophys. Res. Commun., 196: 92-98, 1993.
27. Jackson, J. G., White, M. F., and Yee, D. Insulin receptor substrate-I is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J. Biol. Chem., 273: 9994-10003, 1998.
28. Figueroa, J. A., Sharma, J., Jackson, J. G., McDermott, M. J., Hilsenbeck, S. G., and Yee, D. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J. Cell Physiol., 157: 229-236, 1993.
29. Lammers, R., Gray, A., Schlessinger, J., and Ullrich, A. Differential signaling potential of insulin- and IGF-1-receptor cytoplasmic domains. EMBO J., 8: 1369-1375, 1989.
30. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
31. Twentyman, P. R., and Luscombe, M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br. J. Cancer. 56: 279-285. 1987.
32. McGuire, W. L., Jr., Jackson, J. G., Figueroa, J. A., Shimasaki, S., Powell, D. R., and Yee, D. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action [published erratum appears in J. Natl. Cancer Inst. (Bethesda), 84: 1837, 1992], J. Natl. Cancer Inst. (Bethesda), 84: 1336-1341, 1992.
33. Dufourny, B., Alblas, J., van Teeffelen, H. A., van Schaik, F. M., van der Burg, B., Steenbergh, P. H., and Sussenbach, J. S. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J. Biol. Chem., 272: 31163-31171, 1997.
34. Lewis, G. D., Figari, I., Fendly, B., Wong, W. L., Carter, P., Gorman, C., and Shepard, H. M. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother., 37: 255-263, 1993.
35. Lee, A. V., Gooch, J. L., Oesterreich, S., Guler, R. L., and Yee, D. Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3′-kinase inhibition. Mol. Cell. Biol., 20: 1489-1496, 2000.
36. Clynes, R. A., Towers, T. L., Presta, L. G., and Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med., 6: 443-446, 2000.
37. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., and Ravetch, J. V. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA, 95: 652-656, 1998.
38. Clarke, R. Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res. Treat., 39: 69-86, 1996.
39. Lopes, U. G., Erhardt, P., Yao, R., and Cooper, G. M. p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem., 272: 12893-12896, 1997.
40. Mellman, I., Fuchs, R., and Helenius, A. Acidificafion of the endocytic and exocytic pathways. Annu. Rev. Biochem., 55: 663-700, 1986.
41. D'Ambrosio, C., Ferber, A., Resnicoff. M., and Baserga, R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res., 56: 4013-4020, 1996.
42. Dunn, S. E., Ehrlich, M., Sharp, N. J., Reiss, K., Solomon, G., Hawkins, R., Baserga, R., and Barrett, J. C. A dominant negative mutant of the insulin-like growth factor I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res., 58: 3353-3361, 1998.
43. Liu, X., Turbyville, T., Fritz, A., and Whitesell, L. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res., 58: 5432-5438, 1998.
44. Ciardiello, F., and Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res., 7: 2958-2970, 2001.
45. Albanell, J., Rojo, F., and Baselga, J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin. Oncol., 28: 56-66. 2001.
46. Ullrich, A., Gray, A., Tam, A. W., Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., Kathuria, S., Chen, E., et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J., 5: 2503-2512, 1986.
47. Pautsch, A., Zoephel, A., Ahorn, H., Spevak, W., Hauptmann, R., and Nar, H. Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight into domain movements upon kinase activation. Structure (Camb.), 9: 955-965. 2001.
48. Herbst, R. S., and Langer, C. J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol., 29: 27-36, 2002.
49. Xiong, L., Kasuya, J., Li, S. L., Kato, J., and Fujita-Yamaguchi, Y. Growthstimulatory monoclonal antibodies against human insulin-like growth factor I receptor. Proc. Natl. Acad. Sci. USA, 89: 5356-5360, 1992.
50. Xu, F. J., Boyer, C. M., Bae, D. S., Wu, S., Greenwald, M., O'Briant, K., Yu, Y. H., Mills, G. B., and Bast, R. C., Jr. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. Int. J. Cancer, 59: 242-247, 1994.
51. Shawver, L. K., Mann, E., Elliger, S. S., Dugger, T. C., and Arteaga, C. L. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells. Cancer Res., 54: 1367-1373, 1994.
52. Stancovski, I., Hurwitz, E., Leitner, O., Ullrich, A., Yarden, Y., and Sela, M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc. Natl. Acad. Sci. USA, 88: 8691-8695, 1991.
53. Furlanetto, R. W. Receptor-mediated endocytosis and lysosomal processing of insulin-like growth factor I by mitogenically responsive cells. Endocrinology, 122: 2044-2053, 1988.
54. Hsu, D., Knudson, P. E., Zapf, A., Rolband, G. C., and Olefsky, J. M. NPXY motif in the insulin-like growth factor I receptor is required for efficient ligand-mediated receptor internalization and biological signaling. Endocrinology, 134: 744-750, 1994.
55. Zapf, A., Hsu, D., and Olefsky, J. M. Comparison of the intracellular itineraries of insulin-like growth factor 1 and insulin and their receptors in Rat-I fibroblasts. Endocrinology, 134: 2445-2452, 1994.
56. Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A., and Greene, M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell, 41: 697-706, 1985.
57. Leonessa, F., Green, D., Licht, T., Wright, A., Wingate-Legette, K., Lippman, J., Gottesman, M. M., and Clarke, R. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Br. J. Cancer, 73: 154-161, 1996.
58. Maier, L. A., Xu, F. J., Hester, S., Boyer, C. M., McKenzie, S., Bruskin, A. M., Argon, Y., and Bast, R. C., Jr. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res., 51: 5361-5369, 1991.
59. Brunner, N., Bastert, G. B., Poulsen, H. S., Spang-Thomsen, M., Engelholm, S. A., Vindelov, L., Nielsen. A., Tommerup, N., and Elling, F. Characterization of the T61 human breast carcinoma established in nude mice. Eur. J. Cancer Clin. Oncol., 21: 833-843, 1985.
60. Brunner, N., Spang-Thomsen, M., and Cullen, K. The T61 human breast cancer xenograft: an experimental model of estrogen therapy of breast cancer. Breast Cancer Res. Treat., 39: 87-92, 1996.
61. Reiss, K., Valentinis, B., Tu, X., Xu, S. Q., and Baserga, R. Molecular markers of IGF-I-mediated mitogenesis. Exp. Cell Res., 242: 361-372, 1998.
62. Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., and Pollak, M. Insulin-like growth factor I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. (Bethesda), 93: 1852-1857, 2001.
63. Chakravarti, A., Loeffler, J. S., and Dyson, N. J. Insulin-like growth factor receptor I mediates resistance to antiepidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res., 62: 200-207, 2002.